Dec112017 Anavex Life Sciences Reports Fiscal 2017 Financial Results And Provides Update On Therapeutic Programs December 11, 2017
Nov212017 Anavex Life Sciences Reports Newly Published Data on Alzheimer’s Disease Research Demonstrate the Neuroprotective Features of the Sigma-1 Receptor November 21, 2017
Nov82017 Anavex Life Sciences to Present at the 5th Annual Mental Health Parity Addiction Equity Act Business Roundtable in Washington, DC November 8, 2017
5th Annual Mental health Parity Addiction Equity Act Business Roundtable in Washington DC on November 8, 2017 November 6, 2017
Anavex® Life Sciences presenting at Society for Neuroscience Nov. 11-15, 2017 in Washington DC November 6, 2017
Nov42017 Anavex Life Sciences Presents New Clinical Data of Investigational Alzheimer’s Disease Treatment ANAVEX®2- 73 at 2017 Clinical Trials on Alzheimer’s Disease Meeting November 4, 2017
Oct302017 Anavex Life Sciences Announces Additional Data at The Michael J. Fox Foundation’s Parkinson’s Disease Therapeutics Conference October 30, 2017
Oct272017 Anavex Life Sciences Announces New Data Related to Multiple Sclerosis Presented at 7th ECTRIMS-ACTRIMS Meeting MSPARIS2017 October 27, 2017
Oct122017 Anavex Life Sciences Reports PK and PD Data from Phase 2a Trial of ANAVEX®2-73 in Mild-to-Moderate Alzheimer’s Disease Patients; Conference call today at 8:30am ET October 12, 2017
